Gene EXpression Profiles

(GEX)

AMGIN Ltd. will develop Preventive Personalized Medicine (PPM) in Hong Kong, especially to make gene expression profiles of dogs and cats. For the purpose of it, AMGIN will find causes of obesity related diseases so that AMGIN collects bloods and tissues of dogs and cats in Beijing.

GEX is the most powerful tool for diagnoses and much more effective than other OMICs such like SNPs, Proteome and whatever. DNA sequence and SNPs are useful to analyze our genetic background. Once we know them, we do not need check them up again.

But gene expression is changeable and related with our condition so that we enable to utilize these data for diagnoses. Unfortunately it is a still undeveloped method, therefore it is worth developing methods and making systems.

AMGIN will adopt Serial Analysis of Gene Expression (SAGE) by Next Generation Sequencer (NxtGene) as GEX, because SAGE with a NxtGene is the strongest tool for GEX than other methods in terms of high cost performance, both reliability and amounts of data.

The products and services of AMGIN’s are databases of GEX on dogs and cats as well as funded research by healthcare related companies to use AMGIN’s samples. It is very useful to not only narrow candidates but also research even further. AMGIN will collect human GEX from public databases to compare with and narrow down causes of obesity related diseases so that comparison genomics is very effective to find causes of diseases.

With these profiles, AMGIN then plans to develop and introduce PPM for the dogs and cats as well as human. AMGIN will leverage its expertise to serve the needs of GEX and turn Hong Kong into the leading Biomedical city in the world.

AMGIN has Five Core Businesses on GEX

This is the final goal of whole projects of AMGIN. AMGIN has been strived to find causes of diseases as well as developed diagnosis kits. For the purpose of it, AMGIN will make gene expression profiles on dogs and cats.

Unfortunately this project needs huge money so that AMGIN does not have any equipments and Wet Laboratory. Fortunately AMGIN has a lot of intelligences in this field, because AMGIN also has strong connection with both famous professors and pharmaceutical companies in the world.

Once this project will be launched, AMGIN will be able to find new causes of diseases in 3 years, especially obesity and diabetes fields. The first target of AMGIN is in the obesity area, because market size is huge and it is difficult to find causes so that even a small company with intelligences has a big chance to overwhelm huge company.

After AMGIN’s finding only 1 main gene of causes, the valuation of AMGIN’s will skyrocket. The exit plan of AMGIN’s is just trade-off but not IPO subscription. This is better for investors.